1991
DOI: 10.1159/000471707
|View full text |Cite
|
Sign up to set email alerts
|

Randomized, Double-Blind Trial of Lithostat™ (Acetohydroxamic Acid) in the Palliative Treatment of Infection-Induced Urinary Calculi

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
55
1
5

Year Published

2007
2007
2017
2017

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 146 publications
(61 citation statements)
references
References 12 publications
0
55
1
5
Order By: Relevance
“…In double-blind, placebo-controlled clinical trials, acetohydroxamic acid (Lithostat), a complete nonreversible urease inhibitor, was associated with 17-42% of stone growth versus 46-60% in patients treated with placebo. Side effects occurred in 45-68% of cases [19][20][21] . …”
Section: Treatmentmentioning
confidence: 99%
“…In double-blind, placebo-controlled clinical trials, acetohydroxamic acid (Lithostat), a complete nonreversible urease inhibitor, was associated with 17-42% of stone growth versus 46-60% in patients treated with placebo. Side effects occurred in 45-68% of cases [19][20][21] . …”
Section: Treatmentmentioning
confidence: 99%
“…The urease inhibitor acetohydroxamic acid (AHA) has been studied with limited success and not insignificant side effects. [151][152][153] This agent is not currently available in Canada. A better-tolerated prevention strategy may be low-dose suppressive antibiotic therapy, but the risk of bacterial resistance should be taken into consideration.…”
Section: Index Patient 5: Struvite Stonementioning
confidence: 99%
“…Bu duruma gelen strüvit taşları "geyik boynuzu (staghorn)" taşları olarak adlandırılmaktadır. 57,58 İYE'ler taş oluşum riskini artırdığı için klinisyenin, enfeksiyonların neden olduğu taşlar ile üri-ner sistem taşlarına eşlik eden enfeksiyonu ayırdetmesi gerekmektedir; ancak bu ayrım kolay kolay yapılamamaktadır. Bununla birlikte taş analizi bu ayrımda yardımcı olabilmektedir.…”
Section: İdrar Yolu Enfeksiyonlarıunclassified
“…Bir üreaz inhibitörü olan asetohidroksamik asit eriş-kinlerde başarıyla kullanılıyorsa da çocuklarda ciddi yan etkileri nedeni ile kullanılmamalıdır. 58 Ç Çı ık ka ar r Ç Ça at tı ış şm ma as sı ı Yazarlar herhangi bir çıkar çatışması veya finansal destek bildirmemiştir.…”
Section: Si̇tratunclassified